Cowen and Company’s Inovio Pharmaceuticals INO Stock Holding History

Cowen and Company’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,200	Closed	-$17K	–	459
2020 Q3	$17K	Buy	+8,200	New	+$1.71M	﹤0.01%	364

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cowen and Company's INO Position: Q1 2022 in Review

Cowen and Company sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 7,034 shares — an estimated $421K sold.

Cowen and Company first reported a position in INO in Q3 2020 and held it in 2 quarters. The position peaked at $645K in Q3 2020. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

Cowen and Company reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 7,034 Inovio Pharmaceuticals shares in Q1 2022, an estimated $421K.
Cowen and Company first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 2 quarters.
Cowen and Company's Inovio Pharmaceuticals position peaked at $645K in Q3 2020.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.